Healthcare
Live Price
Offline$8.50
-2.30% today
1Y Change
+59.64%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scilex Holding Company (SCLX) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $8.50 and up 59.6% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -46.5%, EPS growth of -87.8%, a dividend yield of 0.0%. What stands out right now is revenue -46.5%, EPS -87.8%, free cash flow -81.0% with operating margin -900.4% and ROIC 1032.0%. Valuation is more restrained than many high-expectation growth names at price/sales 3.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SCLX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCLX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCLX Max Drawdown
-80.27%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCLX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$23.6M
-24.8% YoY
FY Net Income
-$47.5M
+46.3% YoY
Free Cash Flow
-$31.5M
-9.8% YoY
Revenue Growth
-46.5%
EPS Growth
-87.8%
Gross Margin
59.7%
Net Margin
-1330.4%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 57M | 47M | 38M | 31M | 24M |
| Gross Profit | 40M | 31M | 27M | 28M | 21M |
| Operating Income | -83M | -105M | -51M | -36M | -35M |
| EBITDA | -67M | -109M | -9M | -73M | -31M |
| Net Income | -73M | -114M | -23M | -88M | -48M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 4M | 2M | 4M | 5M |
| Total Assets | 93M | 101M | 87M | 78M | 82M |
| Total Liabilities | 286M | 274M | 50M | 302M | 223M |
| Shareholder Equity | -193M | -173M | 36M | -224M | -142M |
| Total Debt | 38M | 128M | 1M | 155M | 139M |
| Net Debt | 35M | 125M | -774K | 150M | 134M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
31M
-9.8% YoY
Capital Expenditures
25K
Free Cash Flow
31M
-9.8% YoY
Key ratios
Gross Margin
59.7%
Operating Margin
-900.4%
Net Margin
-1330.4%
ROE
190.5%
Debt / Equity
-0.64x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.